We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche Exercises Option for Ophthotech’s Fovista
Roche subsidiary Genentech will exercise its option to commercialize Ophthotech’s wet age-related macular degeneration drug Fovista with Novartis outside the U.S.